Menotropin cost effective for ART in France

Menotropin cost effective for ART in France PharmacoEconomics & Outcomes News 792, p19 - 2 Dec 2017 Menotropin cost effective for ART in France Menotropin (high purified human menopausal gonadotropin [HP-hMG]) appears to be cost effective compared with rFSH (recombinant follicle stimulating hormone) for assisted reproductive technology (ART) in France, according to findings of a study published in Applied Health Economics and Health Policy. A Markov model populated with data from the MERIT and MEGASET trials, or routine ART practice in France, was used to compare the cost effectiveness of menotropin and rFSH in a hypothetical cohort of 30 000 patients undergoing in vitro fertilization/ intracytoplasmic sperm injection (IVF/ICSI) with embryo transfer, from a French healthcare payer perspective. Based on clinical trial data, the estimated total cost per live birth was lower with menotropin than with rFSH (€12 145 vs €14 247), resulting in an estimated incremental cost-effectiveness ratio (ICER) of –€11 616 per live birth. Menotropin was estimated to gain 1289 additional live births compared with rFSH at cost savings of €15.0 million in the total cohort, and was therefore the dominant strategy (more effective and less costly). Based on French clinical data, the estimated cost per live birth was €16 415 with menotropin and €18 7531 with rFSH, resulting in an ICER of –€7719 per live birth. Menotropin was estimated to gain 1097 additional live births compared with rFSH at cost savings of €8.54 million in the total cohort, and was therefore dominant. According to deterministic sensitivity analyses, live birth rate and total gonadotropin doses were the primary drivers of cost effectiveness. Probabilistic sensitivity analysis found that menotropin was the dominant strategy in 71.2% of cases based on clinical trial data and in 50.2% of cases based on French clinical data. "This study highlighted the high total costs of ART in France and demonstrated that potential savings related to the use of a less expensive gonadotropin are higher as effectiveness increases," said the authors. "The results of the present Markov model analysis are consistent with previous findings in other European countries," they noted. * 2016 euros Barriere P, et al. Cost-Effectiveness Analysis of the Gonadotropin Treatments HP- hMG and rFSH for Assisted Reproductive Technology in France: A Markov Model Analysis. Applied Health Economics and Health Policy : 9 Nov 2017. Available from: URL: http://doi.org/10.1007/s40258-017-0361-7 803283344 1173-5503/17/0792-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved PharmacoEconomics & Outcomes News 2 Dec 2017 No. 792 http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png PharmacoEconomics & Outcomes News Springer Journals

Menotropin cost effective for ART in France

Free
1 page
Loading next page...
1 Page
 
/lp/springer_journal/menotropin-cost-effective-for-art-in-france-QeMwHGFSzM
Publisher
Springer International Publishing
Copyright
Copyright © 2017 by Springer International Publishing AG, part of Springer Nature
Subject
Medicine & Public Health; Pharmacoeconomics and Health Outcomes; Quality of Life Research; Health Economics; Public Health
ISSN
1173-5503
eISSN
1179-2043
D.O.I.
10.1007/s40274-017-4542-2
Publisher site
See Article on Publisher Site

Abstract

PharmacoEconomics & Outcomes News 792, p19 - 2 Dec 2017 Menotropin cost effective for ART in France Menotropin (high purified human menopausal gonadotropin [HP-hMG]) appears to be cost effective compared with rFSH (recombinant follicle stimulating hormone) for assisted reproductive technology (ART) in France, according to findings of a study published in Applied Health Economics and Health Policy. A Markov model populated with data from the MERIT and MEGASET trials, or routine ART practice in France, was used to compare the cost effectiveness of menotropin and rFSH in a hypothetical cohort of 30 000 patients undergoing in vitro fertilization/ intracytoplasmic sperm injection (IVF/ICSI) with embryo transfer, from a French healthcare payer perspective. Based on clinical trial data, the estimated total cost per live birth was lower with menotropin than with rFSH (€12 145 vs €14 247), resulting in an estimated incremental cost-effectiveness ratio (ICER) of –€11 616 per live birth. Menotropin was estimated to gain 1289 additional live births compared with rFSH at cost savings of €15.0 million in the total cohort, and was therefore the dominant strategy (more effective and less costly). Based on French clinical data, the estimated cost per live birth was €16 415 with menotropin and €18 7531 with rFSH, resulting in an ICER of –€7719 per live birth. Menotropin was estimated to gain 1097 additional live births compared with rFSH at cost savings of €8.54 million in the total cohort, and was therefore dominant. According to deterministic sensitivity analyses, live birth rate and total gonadotropin doses were the primary drivers of cost effectiveness. Probabilistic sensitivity analysis found that menotropin was the dominant strategy in 71.2% of cases based on clinical trial data and in 50.2% of cases based on French clinical data. "This study highlighted the high total costs of ART in France and demonstrated that potential savings related to the use of a less expensive gonadotropin are higher as effectiveness increases," said the authors. "The results of the present Markov model analysis are consistent with previous findings in other European countries," they noted. * 2016 euros Barriere P, et al. Cost-Effectiveness Analysis of the Gonadotropin Treatments HP- hMG and rFSH for Assisted Reproductive Technology in France: A Markov Model Analysis. Applied Health Economics and Health Policy : 9 Nov 2017. Available from: URL: http://doi.org/10.1007/s40258-017-0361-7 803283344 1173-5503/17/0792-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved PharmacoEconomics & Outcomes News 2 Dec 2017 No. 792

Journal

PharmacoEconomics & Outcomes NewsSpringer Journals

Published: Dec 2, 2017

There are no references for this article.

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Unlimited reading

Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.

Stay up to date

Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.

Organize your research

It’s easy to organize your research with our built-in tools.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve Freelancer

DeepDyve Pro

Price
FREE
$49/month

$360/year
Save searches from
Google Scholar,
PubMed
Create lists to
organize your research
Export lists, citations
Read DeepDyve articles
Abstract access only
Unlimited access to over
18 million full-text articles
Print
20 pages/month
PDF Discount
20% off